Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer

S. J. F. Gerbrandy; L. C. Schreuders; M. D. de Smet

doi:https://doi.org/10.1080/09273940802056273

Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer

S. J. F. Gerbrandy, L. C. Schreuders, M. D. de Smet

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Scopus)

Abstract

BACKGROUND: We report a patient who developed BCG endophthalmitis after BCG immunotherapy for bladder cancer. Comparison of this case with 2 other reported cases reveals a similar pattern of elderly, debilitated and immunocompromised patients with poor response to systemic antituberculous therapy in whom systemic steroids are used concurrently. Age and glucocorticoids are known to lead to thymic involution, reduce cell mediated immunity, and a lowering in the number of naive T cells capable of mounting an effective defense to new infectious agents. CONCLUSIONS: Physicians should be aware of the potential for ocular complications of BCG immunotherapy in the elderly, immunocompromised, on oral steroids

Original language	English
Pages (from-to)	95-97
Journal	Ocular Immunology and Inflammation
Volume	16
Issue number	3
DOIs	https://doi.org/10.1080/09273940802056273
Publication status	Published - 2008

Access to Document

https://doi.org/10.1080/09273940802056273

Cite this

@article{7c9f128c2c664bb8999e24af05aa62d0,

title = "Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer",

abstract = "BACKGROUND: We report a patient who developed BCG endophthalmitis after BCG immunotherapy for bladder cancer. Comparison of this case with 2 other reported cases reveals a similar pattern of elderly, debilitated and immunocompromised patients with poor response to systemic antituberculous therapy in whom systemic steroids are used concurrently. Age and glucocorticoids are known to lead to thymic involution, reduce cell mediated immunity, and a lowering in the number of naive T cells capable of mounting an effective defense to new infectious agents. CONCLUSIONS: Physicians should be aware of the potential for ocular complications of BCG immunotherapy in the elderly, immunocompromised, on oral steroids",

author = "Gerbrandy, {S. J. F.} and Schreuders, {L. C.} and {de Smet}, {M. D.}",

year = "2008",

doi = "https://doi.org/10.1080/09273940802056273",

language = "English",

volume = "16",

pages = "95--97",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer

AU - Gerbrandy, S. J. F.

AU - Schreuders, L. C.

AU - de Smet, M. D.

PY - 2008

Y1 - 2008

N2 - BACKGROUND: We report a patient who developed BCG endophthalmitis after BCG immunotherapy for bladder cancer. Comparison of this case with 2 other reported cases reveals a similar pattern of elderly, debilitated and immunocompromised patients with poor response to systemic antituberculous therapy in whom systemic steroids are used concurrently. Age and glucocorticoids are known to lead to thymic involution, reduce cell mediated immunity, and a lowering in the number of naive T cells capable of mounting an effective defense to new infectious agents. CONCLUSIONS: Physicians should be aware of the potential for ocular complications of BCG immunotherapy in the elderly, immunocompromised, on oral steroids

AB - BACKGROUND: We report a patient who developed BCG endophthalmitis after BCG immunotherapy for bladder cancer. Comparison of this case with 2 other reported cases reveals a similar pattern of elderly, debilitated and immunocompromised patients with poor response to systemic antituberculous therapy in whom systemic steroids are used concurrently. Age and glucocorticoids are known to lead to thymic involution, reduce cell mediated immunity, and a lowering in the number of naive T cells capable of mounting an effective defense to new infectious agents. CONCLUSIONS: Physicians should be aware of the potential for ocular complications of BCG immunotherapy in the elderly, immunocompromised, on oral steroids

U2 - https://doi.org/10.1080/09273940802056273

DO - https://doi.org/10.1080/09273940802056273

M3 - Article

C2 - 18569795

SN - 0927-3948

VL - 16

SP - 95

EP - 97

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 3

ER -